Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-ALK7, the company’s investigational RNA interference (RNAi) ...

ALK genes are found in about 3% to 9% of non–small cell lung cancer (NSCLC) cases, the study shared. These genes drive tumor growth by activating specific signaling pathways that help cancer cells ...

TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is ...

Receptors such as EGFR, HER2, MET and ALK interface with common downstream signaling pathways and 'addiction switching' can occur, either by the inhibition of one receptor triggering a switch to ...

In this context, cellular communication between endothelial cells and perycites is critical. TGF-β signaling pathway is implicated in perycite recruitment and vessel maturation. 1 Upon TGF-β ...

REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, such as the ALK pathway, re-establishes pathways ...

REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, such as the ALK pathway, re-establishes ...

It is challenging to balance physician autonomy with rigid clinical pathways when it comes to these institutional decisions, which often are made by a small group. The management of ALK-positive ...